Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06472076 · ClinicalTrials.gov registry record · Phase 3

A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

A Phase 3 study of Lung Cancer, Non-Small Cell, sponsored by GlaxoSmithKline.

Active
Registry status
Phase 3
Development phase
88
Enrollment target
20
Study locations

NCT06472076 is a Phase 3 study of Lung Cancer, Non-Small Cell that is active but no longer recruiting, run by GlaxoSmithKline. The registered enrollment target is 88 participants, below the 322-participant average among 10 other Lung Cancer, Non-Small Cell trials with a reported enrollment target (73% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06472076, a Phase 3 study of Lung Cancer, Non-Small Cell, is active but no longer recruiting, sponsored by GlaxoSmithKline.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
88 participants
Enrollment target
20
Study locations

Study Summary

The goal of this clinical trial is to evaluate the safety and tolerability profile of dostarlimab in combination with belrestotug when compared with pembrolizumab and placebo in participants with previously untreated, unresectable, locally advanced or metastatic PD-L1 high NSCLC.

Conditions Studied

Lung Cancer, Non-Small Cell

Interventions

  • BIOLOGICAL Pembrolizumab
  • DRUG Placebo
  • BIOLOGICAL Dostarlimab
  • BIOLOGICAL Belrestotug

Study Locations (20)

Other

  • GSK Investigational Site - Buenos Aires
  • GSK Investigational Site - Cipoletti Rio Negro
  • GSK Investigational Site - Ciudad Autonoma de Buenos Aire
  • GSK Investigational Site - Ciudad Autonoma de Bueno
  • GSK Investigational Site - Córdoba
  • GSK Investigational Site - Florida
  • GSK Investigational Site - Mendoza
  • GSK Investigational Site - Rosario
  • GSK Investigational Site - Rosario
  • GSK Investigational Site - San Miguel de Tucumán
  • GSK Investigational Site - Hasselt

Kentucky

  • GSK Investigational Site - Lexington
  • GSK Investigational Site - Lexington

Florida

  • GSK Investigational Site - Ocala

Hawaii

  • GSK Investigational Site - Honolulu

Michigan

  • GSK Investigational Site - Ann Arbor

Nebraska

  • GSK Investigational Site - Omaha

Tennessee

  • GSK Investigational Site - Nashville

Texas

  • GSK Investigational Site - Fort Worth

Trial Details

FieldValue
Enrollment Target 88 participants
Start Date 2024-06-10
Est. Completion 2027-02-02
Phase Phase 3

Sponsor

GlaxoSmithKline

1,345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06472076

The ClinicalTrials.gov registry entry for NCT06472076 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 322-participant average among 10 other Lung Cancer, Non-Small Cell trials with a reported enrollment target (73% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Lung Cancer, Non-Small Cell appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.

NCT06472076 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, Kentucky, Florida.

Frequently Asked Questions

What is clinical trial NCT06472076 about?

NCT06472076 is a clinical study titled "A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)". The goal of this clinical trial is to evaluate the safety and tolerability profile of dostarlimab in combination with belrestotug when compared with pembrolizumab and placebo in participants with previously untreated, unresectable, locally advanced or metastatic PD-L1 high NSCLC.

What is the current status of trial NCT06472076?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 88 participants. The study started on 2024-06-10. Estimated completion is 2027-02-02.

What conditions does trial NCT06472076 study?

This clinical trial studies the following conditions: Lung Cancer, Non-Small Cell.

What interventions are being tested in trial NCT06472076?

The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Placebo (DRUG), Dostarlimab (BIOLOGICAL), Belrestotug (BIOLOGICAL).

Who is sponsoring clinical trial NCT06472076?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06472076 being conducted?

This trial has 20 study locations across Florida, Hawaii, Kentucky, Michigan, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lung Cancer, Non-Small Cell

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lung Cancer, Non-Small Cell

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.